Common use of Supply of the Compounds Clause in Contracts

Supply of the Compounds. Vaximm and the Alliance will each supply, or cause to be supplied, the quantities of its respective Compound set forth on Appendix B on the timelines set forth in Appendix B, in each case, for use in the Study. In the event that Vaximm determines that the quantities of Compounds set forth on Appendix B are not sufficient to complete the Study (due, for example, to the addition of Study sites or countries), Vaximm shall so notify the Alliance, and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may be provided. Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the event that either Party is not supplying its Compound in accordance with the terms of this Agreement, or is allocating under Section 8.10, then the other Party shall have no obligation to supply its Compound, or may allocate proportionally.

Appears in 1 contract

Samples: Clinical Trial Collaboration and Supply Agreement

AutoNDA by SimpleDocs

Supply of the Compounds. Vaximm Advaxis and the Alliance Merck will each use commercially reasonable efforts to supply, or cause to be supplied, the quantities of its respective Compound as are set forth on Appendix B C, on the timelines set forth in Appendix BC, in each case, for use in the StudyCollaboration Program. In the event that Vaximm the Party conducting the Collaboration Program determines that the quantities of Compounds set forth on Appendix B C are not sufficient to complete the Study (dueStudy, for example, to the addition of Study sites or countries), Vaximm such Party shall so notify the Allianceother Party, and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may shall be provided. Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the event that either Party is not supplying its Compound in accordance with the terms of this Agreement, or is allocating under Section 8.10, then the other Party shall have no obligation to supply its Compound, or may allocate proportionally.

Appears in 1 contract

Samples: Clinical Trial Collaboration and Supply Agreement (Advaxis, Inc.)

Supply of the Compounds. Vaximm and Checkmate, the Alliance will and Pfizer shall each supply, or cause to be supplied, the quantities of its respective Compound set forth on Appendix B on the timelines set forth in Appendix B, in each case, for use in the Study. In the event that Vaximm Pfizer determines that the quantities of Compounds set forth on Appendix B are not sufficient to complete the Study (due, for example, to the addition of Study sites or countries), Vaximm Pfizer shall so notify the AllianceAlliance and Checkmate, and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may be provided. Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the event that either Party is not supplying its Compound in accordance with the terms of this Agreement, or is allocating under Section 8.10, then the other Party shall have no obligation to supply its Compound, or may allocate proportionally.

Appears in 1 contract

Samples: Trial Collaboration and Supply Agreement (Checkmate Pharmaceuticals, Inc.)

AutoNDA by SimpleDocs

Supply of the Compounds. Vaximm Incyte and the Alliance Advaxis will each use commercially reasonable efforts to supply, or cause to be supplied, the quantities of its respective Compound as are set forth on in Appendix B D, on the timelines set forth in Appendix BD, in each case, for use in the Study. In the event that Vaximm the Party conducting the Study determines that the quantities of Compounds set forth on Appendix B D are not sufficient to complete the Study (dueStudy, for example, to the addition of Study sites or countries), Vaximm such Party shall so notify the Allianceother Party, and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may shall be provided. Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the event that either Party is not supplying its Compound in accordance with the terms of this Agreement, or is allocating under Section 8.10, then the other Party shall have no obligation to supply its Compound, or may allocate proportionally.

Appears in 1 contract

Samples: Clinical Study Collaboration Agreement (Advaxis, Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.